Alexion Pharmaceuticals’ Co-Development Partnership with Complement Pharma

Ambrogio Visconti North America, North America Legal Chronicle

Foley Hoag LLP recently advised global biopharmaceutical company Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in a partnership with Complement Pharma to co-develop a pre-clinical C6 complement inhibitor for…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:

Author: Ambrogio Visconti

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here